Abstract
The present study was undertaken to evaluate the presence of GnRH receptors (GnRH-R) in breast cancer and not-involved breast tissue, and the relationships between GnRH-R and receptors for estrogen (ER) and progesterone (PgR) in the same tissues. Utilizing a tritiated natural GnRH in order to assay the native receptor binding we analyzed the level of binding sites for GnRH in membranes derived from 90 breast tumors and in 40 cases from neighboring, not-involved breast tissue. GnRH-R was found both in cancer and normal tissues. The prevalence for GnRH-R was higher in tumor than in not-tumor tissue (45% vs 39%, respectively), but the overall levels were not significantly different (15.9±24 fmol/mg protein vs 18.2±39 fmol/mg protein, respectively). The only statistically different content of GnRH-R we found concerned PgR negative vs PgR positive tumor tissues (mean content: 23 vs 11 fmol/mg protein, respectively in PgRand PgR+ tumors, p=0.03 by t test); furthermore the proportion of GnRH-R positive cases in the tumor resulted significantly higher in premenopausal patients vs postmenopausal (56% vs 32%, by Chi square test, p<0.05). The GnRH receptors status of primary tumor and contiguous notinvolved breast tissue resulted associated (overall agreement: 63%, p<0.05) but no specific steroid patterns for GnRH-R positivity was observed.
Similar content being viewed by others
References
Kaufmann M. Zoladex in treatment of premenopausal metastatic breast cancer patients. Horm. Res. 1989, 32(Suppl. 1): 202–205.
Klijn J.G.M., De Jong F.H., Lamberts S.W.J., Blankenstein M.A. LHRH-agonist treatment in clinical and experimental human breast cancer. J. Steroid Biochem. 1985, 23: 867–873.
Nicholson R.I., Walker K.J., MeClelland R.A., Dixon A., Robertson R.I., Blamcy R.W. Zoladex plus tamoxifen versus Zoladex alone in pre and perimenopausal metastatic breast cancer. J. Steroid Biochem. Molec. Biol. 1990, 37: 989–995.
Fekete M., Zalatmai A., Comaru-Schally A.M., Schally A.V. Membrane receptors for peptides in experimental and human pancreatic cancers. Pancreas 1989, 4: 521–528.
Srkalovic G., Wittliff J.L., Schally A.V. Detection and partial characterization of receptors for (D-Trp6)-luteinizing-hormone releasing hormone and epidermal growth factor in human endometrial carcinoma. Cancer Res. 1990, 50: 1841–1846.
Emons G., Pahwa G.S., Brack C., Sturm R., Oberheuser F., Knuppen R. Gonadotrophin-releasing-hormone binding sites in human epitelial ovarian carcinoma. Eur. J. Cancer Clin. Oncol. 1989, 25: 215–221.
Eidne K.A., Flanagan C.A., Harris N.S., Millar R.P. Gonadotrophin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists. J. Clin. Endocrinol. Metab. 1987, 64: 425–432.
Miller W.R., Scott W.N., Morris R., Fraser N.M., Sharpe R.M. Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 1985, 313: 231–233.
Fekete M., Wittliff J.L., Schally A.V. Characteristics and distribution of receptors for (D-Trp6)-luteinizing-hormone releasing hormone, somatostatin, epidermal grow factor and sex steroids in 500 biopsy samples of human breast cancer. J. Clin. Lab. Analysis 1989, 3: 137–147.
Baumann K.H., Kiesel L., Kaumann M., Bastert G., Runnebaurn B. Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters. Breast Cancer Res. Treat. 1993, 25: 37–46.
Mullen P., Bramley T., Menzies G., Miller B. Failure to detect gonadotrophin-releasing hormone receptors in human benign and malignant breast tissues and in MCF-7 and MDA-MB-231 cancer cells. Eur. J. Cancer 1993, 29 A: 248–252.
Chatzaki E., Bax C.M.R., Eidne K.A., Anderson L., Grudzinskas J.G., Gallagher C.J. The expression of gonadotropin-releasing hormone and its receptor in endometrial cancer, and its relevance as an autocrine growth-factor. Cancer Res. 1996, 56: 2059–2065.
Bazam T., Koch Y., Hazum E., Fridkin M. Gonadotropin-releasing hormone in milk. Science 1977, 198: 300–302.
Harris N., Dutlow C., Eidne K.A., Dongk W., Roberts J., Millar R. Gonadotropin-releasing hormone gene expression in MDA-MB-231 and ZR-75-1 breast carcinoma cell lines. Cancer Res. 1991, 51: 2577–2581.
Duval D.L., Nelson S.E., Clay C.M. The tripartite basal enhancer of the gonadotropin-releasing hormone (GnRH) receptor gene promoter regulates cell-specific expression through a novel GnRH receptor activating sequence. Mol. Endocrinol. 1997, 11: 1814–1821.
Reshkin S.J., Albarani V., Pezzetta A., Marinaccio M., Paradiso A. Gonadotrophin releasing hormone (GnRH) receptor and steroid receptors in human uterine leiomyoma, myometrium and endometrium. Int. J. Oncol. 1997, 11: 603–607.
Fisher E.R., Gregorio R.M., Fisher B. The pathology of invasive breast cancer: a syllabus derived from findings of the NSABP. Cancer 1975, 36: 1–85.
Piffanelli A., Pelizzola D., Giovannini G., Catozzi L., Faggioli L., Giganti M. Characterization of laboratory working standards for quality control of immunometric and radiometric estrogen receptor assays. Tumori 1989, 75: 550–556.
Waddel/Hill. In: J. Lab. Clin. Med. 1956, 48: 311–314.
Scatchard G. The attractions of proteins for small molecules and ions. Ann. N.Y. Acad. Sci 1949, 51: 660–672.
Paradiso A., Mangia A., Barletta A., Fusilli S., Marzullo F., Schittulli F., De Lena M. Heterogeneity of intratumor proliferative activity in primary breast cancer: biological and clinical aspects. Eur. J. Cancer 1995, 31A: 911–916.
Kakar S.S., Grizzle W.E., Neill J.D. The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary. Mol. Cell. Endocrinol. 1994, 106: 146–149.
Kottler M.L., Starzec A., Carre M.C., Lagarde J.P., Martin A., Counis R. The genes for gonadotropin-releasing hormone and its receptor are expressed in human breast with fibrocystic disease and cancer. Int. J. Cancer 1997, 71: 595–599.
Eidne K.A., Flanagan C.A., Millar R.P. Gonadotropin-releasing hormone binding sites in human breast carcinoma. Science 1985, 229: 989–991.
Reshkin S.J., Pezzetta A., Albarani V., Schittulli F. Paradiso A. Characterization of a 3H-GnRH method for the measurement of GnRH binding sites in human breast cancer and breast cancer cell lines. Int. J. Oncol. 1995, 7: 371–375.
Radovick S., Ticknor C.M., Nakayama Y., Notides A.L.C., Raham A., Weintraub B.D., Cutler G.B.Jr., Wondisford E.E. Evidence for direct estrogen regulation of the human gonadotropin releasing hormone gene. J. Clin. Invest. 1991, 88: 1649–1655.
Motta M. Direct antiproliferative effect of LHRH agonists on human prostatic tumor cells: possible mechanism of action. Gynecol. Endocrinol. 1999, 13 (Suppl 1): 11.
Author information
Authors and Affiliations
Corresponding author
Additional information
Finanziato parzialmente da AIRC e CNR
Rights and permissions
About this article
Cite this article
Paradiso, A., Pezzetta, A., Cellamare, G. et al. GnRH receptors in human breast cancer and its contiguous not-involved breast tissue. J Endocrinol Invest 23, 90–96 (2000). https://doi.org/10.1007/BF03343685
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03343685